Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 15/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | AGER | Q15109 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3485668 | 0.89 | GPR119 (0.58) | GPR119MEN1KMT2ANPC1RAB9A | |
| SCHEMBL3487293 | 0.86 | GPR119 (0.50) | GPR119ADORA2A | |
| SCHEMBL3486622 | 0.86 | GPR119 (0.50) | GPR119 | |
| SCHEMBL3486544 | 0.85 | GPR119 (0.61) | GPR119MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3487738 | 0.84 | GPR119 (0.59) | GPR119MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3486318 | 0.81 | GPR119 (0.68) | GPR119 | |
| SCHEMBL3486413 | 0.81 | GPR119 (0.61) | GPR119MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3487767 | 0.81 | GPR119 (0.76) | GPR119MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3486803 | 0.80 | GPR119 (0.62) | GPR119MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL28898382 | 0.79 | NPC1 (0.62) | GPR119MEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399485-B2 | Acyl bipiperidinyl compounds useful as GPR 119 agonists | MERCK SHARP & DOHME CORP. (US) | 2013-03-19 | — | — | US | claimed |
| US-8445499-B2 | Bipiperidinyl compounds, compositions, containing such compounds and methods of treatment | MERCK SHARP & DOHME CORP. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8445499-B2 | Bipiperidinyl compounds, compositions, containing such compounds and methods of treatment | MERCK SHARP & DOHME CORP. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8445499-B2 | Bipiperidinyl compounds, compositions, containing such compounds and methods of treatment | MERCK SHARP & DOHME CORP. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8399485-B2 | Acyl bipiperidinyl compounds useful as GPR 119 agonists | MERCK SHARP & DOHME CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399485-B2 | Acyl bipiperidinyl compounds useful as GPR 119 agonists | MERCK SHARP & DOHME CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399485-B2 | Acyl bipiperidinyl compounds useful as GPR 119 agonists | MERCK SHARP & DOHME CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120178681-A1 | BIPIPERIDINYL COMPOUNDS, COMPOSITIONS, CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178681-A1 | BIPIPERIDINYL COMPOUNDS, COMPOSITIONS, CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178681-A1 | BIPIPERIDINYL COMPOUNDS, COMPOSITIONS, CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20100075987-A1 | ACYL BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. | 2010-03-25 | — | — | US | disclosed |
| US-20100075987-A1 | ACYL BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. | 2010-03-25 | — | — | US | disclosed |
| US-20100075987-A1 | ACYL BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. | 2010-03-25 | — | — | US | disclosed |
| US-20100029688-A1 | BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. | 2010-02-04 | — | — | US | disclosed |
| US-20100029688-A1 | BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. | 2010-02-04 | — | — | US | disclosed |
| US-20100029688-A1 | BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. | 2010-02-04 | — | — | US | disclosed |
| WO-2008085316-A1 | BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008076243-A2 | ACYL BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075987-A1 | ACYL BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | GPR119, GPR27, FFAR2 | GPR119 1/4885MEN1 4599/4885ALDH1A1 2889/4885 |
| US-20100029688-A1 | BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | GPR119, GPR139, GPR27 | GPR119 1/4885MEN1 4270/4885ALDH1A1 3273/4885 |
| US-20120178681-A1 | BIPIPERIDINYL COMPOUNDS, COMPOSITIONS, CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | GPR119, GPR139, GPR27 | GPR119 1/4885MEN1 4495/4885ALDH1A1 3200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.